More articles from Point and Counterpoint
- Screening mammography starting at age 40: Still relevant
In women in their 40s, the incidence of breast cancer is low but the risk of a tumor being aggressive is especially high.
- Annual mammography starting at age 40: More talk, less action?
In view of the potential harm, we question annual screening starting at age 40.
- The apples and oranges of cost-effectiveness: A rejoinder
A recent CCJM commentary used straw men to indict cost-effectiveness research.
- Interpreting the Courage Trial
We are fortunate to have a point-counterpoint between Dr. William Boden, the principal investigator of the Clinical Outcomes Utilizing Percutaneous Coronary Revascularization and Aggressive Drug Evaluation (COURAGE) trial, and Dr. Dean Kereiakes, a leading interventional cardiologist.
- Cox - 2 Inhibitors and Cardiovascular Risk
Unless a clear cause-and-effect relationship can be proved between COX-2 inhibitors and cardiovascular events, we should go on using these drugs.
- Cox - 2 Inhibitors and Cardiovascular Risk
Our study had limitations, but we believe our hypothesis is plausible, our methods were valid, and our conclusions are sound.